Perrigo bought the rights to Entocort, a drug for mild to moderate Crohn’s disease, for $380 million. Additionally, Perrigo plans to acquire generic Entocort capsules marketed by Par Pharmaceuticals.
“Our agreement with Perrigo completes the global divestment of Entocort, emphasizing our strategic focus on three main therapy areas and providing further simplification of our supply chain,” Luke Miels, an AstraZeneca executive vice president.
More articles on gastroenterology:
7 ways 2016 CMS payment updates affect gastroenterology
Defining moments: The top 2015 highlights in GI
4 GI physicians in the news – Nov. 20, 2015
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
